ArticleMolecular medicine reports2026
Effects of ALDH2 gene expression on the oxidative stress‑mediated NF‑κB/mTOR pathway in ketamine‑induced cystitis.
Article in Molecular medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aldehyde dehydrogenase 2 (ALDH2) serves an important role in regulating the development of organ injury. The present study aimed to investigate the effects of ALDH2 gene expression on the oxidative stress‑mediated NF‑κB/mTOR pathway in ketamine (Ket)‑induced cystitis (KIC). Primarily, human bladder epithelial cells of the SV‑HUC‑1 cell line were divided into groups for incubation with different concentrations of Ket: 0, 0.5, 1, 1.5 and 2 mM. ALDH2 protein expression was then detected after 48 h of incubation with Ket. Subsequently, SV‑HUC‑1 cells were separated into a number of treatment groups, including: i) Control groups, comprising negative control (NC), NC + mTOR activator MHY1485 (Act), NC + Ket and NC + Ket + Act groups; ii) ALDH2 knockdown groups that were transfected with siRNA sequences targeting ALDH2 (si‑ALDH2), including si‑ALDH2, si‑ALDH2 + Act, si‑ALDH2 + Ket and si‑ALDH2 + Ket + Act groups; and iii) ALDH2 overexpression (OE‑ALDH2) transfection groups, comprising OE‑ALDH2, OE‑ALDH2 + Act, OE‑ALDH2 + Ket and OE‑ALDH2 + Ket + Act groups. The levels of apoptosis, oxidative stress and inflammatory protein expression were assessed in each group. The results of the present study demonstrated that ALDH2 protein expression was significantly higher after treatment with Ket compared with the control group. Further analysis revealed that the si‑ALDH2 + Ket group demonstrated the highest levels of apoptosis, oxidative stress and inflammatory protein expression amongst all treatment groups. The levels of these indicators notably improved in the OE‑ALDH2 + Ket group compared with the NC + Ket group. Therefore, the results of the present study revealed that ALDH2 overexpression reduced Ket‑induced apoptosis, oxidative stress and inflammatory protein expression. Furthermore, co‑treatment with Act was shown to mitigate these factors. Additionally, ALDH2 may have modulated the inflammatory response by promoting mTOR activation and inhibiting NF‑κB phosphorylation. The present study concluded that ALDH2 may represent a novel target for KIC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.